期刊
LEUKEMIA & LYMPHOMA
卷 50, 期 1, 页码 47-53出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190802601122
关键词
Idiotype; vaccination; follicular lymphoma; boosters
资金
- Ministry of Science and Technology of the Government of Spain (CICYT)
- Ministry of Health of the Government of Spain (FIS)
- Department of Health and the Department of Education of the Government of Navarra
- UTE
During the last 2 decades, idiotypic vaccination has provided proof of principle of biological efficacy, clinical efficacy and clinical benefit in small follicular lymphoma trials. However, with the exception of anecdotal reports, most patients have received no more than 10 doses of their customised idiotype (Id) vaccine. Therefore, it is not known whether prolonged usage of idiotypic vaccination is safe. Since 2002, 18 previously treated patients with follicular lymphoma have received extended idiotypic vaccination at our institution outside clinical trials. Vaccination was provided as a compassionate alternative to no further treatment, and was meant to be stopped only upon complete consumption of the available patient- and tumor-specific vaccine [Id-keyhole limpet hemocyanin+granulocyte-macrophage colony-stimulating factor (Id-KLH+GM-CSF)], or in case of disease relapse or any serious non-local toxicity. So far, 18 patients have received an average of 18 doses of Id vaccine (median: 17; mean: 18; range: 10-31). Eleven patients are still actively receiving idiotypic vaccination: some of them are now over more than 6 years. Toxicity has been systematically negligible and mostly local. No patient has abandoned the vaccination program because of toxicity. Prolonged idiotypic vaccination with the soluble protein Id-KLH+GM-CSF formulation is safe and well tolerated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据